Equillium (EQ) Convertible Debt (2017 - 2018)

Equillium's (EQ) quarterly Convertible Debt came in at $10.3 million in Q3 2018, up 47.56% on a QoQ basis from $7.0 million in Q4 2017.

Equillium (EQ) Convertible Debt (2017 - 2018) Analysis & Trends

Equillium (EQ) has 2 years of Convertible Debt data on file, last reported at $10.3 million in Q3 2018.

On a quarterly basis, Convertible Debt changed N/A year-over-year to $10.3 million in Q3 2018; TTM through Sep 2018 was $10.3 million, a N/A change from a year earlier, with the FY2017 full-year figure at $7.0 million, changed N/A from the prior year.
Convertible Debt for Q3 2018 stood at $10.3 million, up from $7.0 million in the prior quarter.
Over the last five years, Convertible Debt for EQ reached as high as $10.3 million in Q3 2018 and fell as low as $7.0 million in Q4 2017.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Oculis Holding AG	68,785.72 Bn	68,785.72 Bn	-
2	Nanobiotix	1,895.57 Bn	1,895.51 Bn	-
3	BeOne Medicines	471.35 Bn	466.56 Bn	1.35 Bn
4	NuCana	279.75 Bn	279.75 Bn	-
5	Vertex Pharmaceuticals	120.24 Bn	113.00 Bn	2.59 Bn
6	Regeneron Pharmaceuticals	67.80 Bn	59.04 Bn	3.31 Bn
7	Belite Bio	62.51 Bn	62.51 Bn	-
8	Argenx Se	57.38 Bn	57.38 Bn	1.41 Bn
9	Revolution Medicines	37.78 Bn	37.78 Bn	-
10	Equillium	258.99 Mn	258.99 Mn	-

Download Data

Date	Value
Sep 30, 2018	10.32 Mn
Dec 31, 2017	6.99 Mn